Head to Head Contrast: Biodesix (NASDAQ:BDSX) vs. Renalytix (NASDAQ:RNLX)

Renalytix (NASDAQ:RNLXGet Free Report) and Biodesix (NASDAQ:BDSXGet Free Report) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Analyst Ratings

This is a summary of current recommendations and price targets for Renalytix and Biodesix, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Renalytix 0 0 0 0 N/A
Biodesix 0 0 5 0 3.00

Biodesix has a consensus target price of $3.10, suggesting a potential upside of 91.36%. Given Biodesix’s higher probable upside, analysts plainly believe Biodesix is more favorable than Renalytix.

Profitability

This table compares Renalytix and Biodesix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Renalytix -1,687.80% -1,008.88% -205.46%
Biodesix -85.80% -29,379.44% -52.08%

Risk & Volatility

Renalytix has a beta of 2.78, indicating that its stock price is 178% more volatile than the S&P 500. Comparatively, Biodesix has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.

Insider and Institutional Ownership

9.9% of Renalytix shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 17.8% of Renalytix shares are held by insiders. Comparatively, 69.2% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Renalytix and Biodesix’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Renalytix $2.22 million 10.49 -$45.61 million ($0.39) -0.77
Biodesix $49.09 million 3.78 -$52.15 million ($0.55) -2.95

Renalytix has higher earnings, but lower revenue than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

Summary

Biodesix beats Renalytix on 7 of the 13 factors compared between the two stocks.

About Renalytix

(Get Free Report)

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.

About Biodesix

(Get Free Report)

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.